Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-18
2000-02-01
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514912, A61K 31445
Patent
active
060203528
ABSTRACT:
The use of polyamine site antagonists in treating ischemic disorders of the retina and optic nerve head are disclosed. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.
REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
Embase Abstract of L'angiosclerose, Oculaire 1977. Ardouin et al.
Cornand, et al., Mediterr. Med., "Notre experience du tartrate d'ifenprodil (Validex) en ophthalmologie," 7(191): 105-107, May 2, 1979.
Crampinchi, et al., Bull. Mem. Soc. Fr. Ophthalm., "Traitement par injections repetees de vasodilatateurs des nevrites optiques alcoolo-nicotiniques," 89:339-341, 1977.
Morgan, R., Can. J. Ophthalmol., "Open-angle glaucoma: An epidemiologist's view," 7(1):75-79, 1972.
Zeevalk, et al., Brain Res., "Action of the anti-ischemic agent ifenprodil on N-methyl-D-aspartate and kainate-mediated excitotoxicity," 522(1):135-139, 1990.
Kapin, et al., Soc. Neurisci. Abstr., "Protective effect of the polyamine antagonist, eliprodil hydrochloride in retina subjected to an excitotoxic-or ischemic insult," 22(1-3):1279, 1996.
David, P., et al., "Involvement of excitatory neurotransmitters in the damage produced in chick embryo retinas by anoxia and extracellular high potassium," Exp. Eye Res., 46: 657-662 (1988).
Massey, S., "Cell types using glutamate as a neurotransmitter in the vertebrate retina," Progress in Retinal Research, 9:339-425 (1990).
Miller, R. F. and M. M. Slaughter, "Excitatory amino acid receptors in the vertebrate retina," Retinal Transmitters and Modulators, II:123-160 (1985).
Benveniste, H. et al., "Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis," J. Neurochem., 43(5):1369-1374 (1984).
Olney, J. W., "Inciting excitotoxic cytocide among central neurons," Adv. Exp. Med. Biol., 203:631-645 (1986).
Sattayasai, et al., "Morphology of quisqualate-induced neurotoxicity in the chicken retina," Invest. Ophthalmol. Vis. Sci., 28:106-117 (1987).
Tung, et al., "A quantitative analysis of the effects of excitatory neurotoxins on retinal ganglion cells in the chick," Visual Neurosci., 4:217-223 (1990).
Sisk, et al., "histological changes in the inner retina of albino rats following intravitreal injetion of monosodium L-glutamate," Graefe's Arch. Clin. Exp. Ophthalmol., 223:250-258 (1985).
Siliprandi, et al., "N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina," Visual Neurosci., 8:567-573 (1992).
Reif-Lehrer, et al., "Effects of monosodium glutamate on chick embryo retina in culture," Invest. Ophthalmol. Vis. Sci., 14(2):114-124 (1975).
Blanks, J. C., "Effects of monosodium glutamate on the isolated retina of the chick embryo as a function of age: A morphological study," Exp. Eye. Res., 35:105-124 (1981).
Olney, et al., "The role of specific ions in glutamate neurotoxicity," Neurosci. Lett., 65:65-71 (1986).
Olney, et al., "The anti-excitotoxic effects of certain anesthetics, analgesics and sedative-hypnotics," Neurosci. Lett., 68:29-34 (1986).
Price, et al., "CNQX potently and selectively blocks kainate excitotoxicity in the chick embryo retina," Soc. Neurosci. Abst., 14:418 (1988).
Caprioli, et al., "Large retinal ganglion cells are more susceptible to excitotoxic and hypoxic injury than small cells," Invest. Ophthalmol. Vis. Sci., 34(Suppl):1429 (1993).
Cummins, et al., "Electrophysiology of cultured retinal ganglion cells to investigate basic mechanics of damage," Glaucoma Update IV, 59-65 (1991).
Sucher, et al., "N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro," J. Neurosci., 11(4):966-971 (1991).
Lipton, S.A., "Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide," TINS,16(12):527-532 (1993).
Yoon, Y. H., and Marmor, M. F., "Dextromethorphan Protects Retina Against Ischemic Injury In Vivo," Arch. Ophthalmol., 107:409-411 (1989); and.
Gupta, L. Y., and Marmor, M. F., "Mannitol, Dextromethorphan, and Catalase Minimize Ischemic Damage to Retinal Pigment Epithelium and Retina," Arch. Ophthalmol., 111:384-388 (1993).
DeSantis, Jr. Louis
Kapin Michael A.
Langer Salomon
Scatton Bernard
Fay Zohreh
Synthelabo
Yeager Sally
LandOfFree
Treatment of ischemic disorders of the retina and optic nerve he does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of ischemic disorders of the retina and optic nerve he, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of ischemic disorders of the retina and optic nerve he will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-937841